← Back to Screener
Nuvectis Pharma, Inc. Common Stock (NVCT)
Price$8.33
Favorite Metrics
Price vs S&P 500 (26W)40.58%
Price vs S&P 500 (4W)-1.35%
Market Capitalization$235.78M
All Metrics
Book Value / Share (Quarterly)$0.72
P/TBV (Annual)9.99x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.62
Price vs S&P 500 (YTD)13.74%
EPS (TTM)$-1.21
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$-1.21
EPS (Annual)$-1.21
ROI (Annual)-143.61%
Cash / Share (Quarterly)$1.23
ROA (Last FY)-83.39%
EBITD / Share (TTM)$-1.26
ROE (5Y Avg)-191.98%
Cash Flow / Share (Annual)$-0.62
P/B Ratio12.80x
P/B Ratio (Quarterly)10.50x
Net Income / Employee (Annual)$-2
ROA (TTM)-84.99%
EPS Incl Extra (Annual)$-1.21
Current Ratio (Annual)2.38x
Quick Ratio (Quarterly)2.38x
3-Month Avg Trading Volume0.07M
52-Week Price Return2.30%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.96
52-Week High$11.52
EPS Excl Extra (Annual)$-1.21
26-Week Price Return49.33%
Quick Ratio (Annual)2.38x
13-Week Price Return5.83%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.38x
Enterprise Value$204.142
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.23
3-Month Return Std Dev44.02%
Net Income / Employee (TTM)$-2
ROE (Last FY)-143.61%
EPS Basic Excl Extra (Annual)$-1.21
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.21
ROI (TTM)-131.80%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.97
Price vs S&P 500 (52W)-32.80%
Year-to-Date Return17.88%
5-Day Price Return5.20%
EPS Normalized (Annual)$-1.21
ROA (5Y Avg)-117.72%
Month-to-Date Return15.14%
Cash Flow / Share (TTM)$-1.03
EBITD / Share (Annual)$-1.26
ROI (5Y Avg)-191.98%
EPS Basic Excl Extra (TTM)$-1.21
P/TBV (Quarterly)8.51x
P/B Ratio (Annual)10.50x
Book Value / Share (Annual)$0.72
Price vs S&P 500 (13W)2.96%
Beta-0.07x
Revenue / Share (TTM)$0.00
ROE (TTM)-131.80%
52-Week Low$5.55
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.17
4.17
4.17
4.17
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NVCTNuvectis Pharma, Inc. Common Stock | — | — | — | — | $8.33 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Nuvectis Pharma is a biopharmaceutical company focused on precision oncology. It develops novel, targeted small-molecule therapeutics for cancer patients with specific genetic profiles. The company's pipeline includes NXP800 and NXP900.